UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 38

Sortiert nach

Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Journal of clinical oncology, 2011-03, Vol.29 (9), p.1175-1181

2011

Volltextzugriff (PDF)

Effect of Red Blood Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm-Associated Myelofibrosis

Clinical lymphoma, myeloma and leukemia, 2015-11, Vol.15 (11), p.e151-e156

2015

Volltextzugriff (PDF)

Real‐world chemotherapy treatment patterns in metastatic non–small cell lung cancer: Are patients undertreated?

Cancer, 2015-08, Vol.121 (15), p.2562-2569

2015

Volltextzugriff (PDF)

A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

Leukemia & lymphoma, 2021-06, Vol.62 (7), p.1721-1729

2021

Volltextzugriff (PDF)

Patient-reported acute fatigue in elderly breast cancer patients treated with and without regional nodal radiation

Breast cancer research and treatment, 2020-09, Vol.183 (2), p.391-401

2020

Volltextzugriff (PDF)

Ultracentral Tumors Treated With Stereotactic Body Radiotherapy: Single-Institution Experience

Clinical lung cancer, 2018-09, Vol.19 (5), p.e803-e810

2018

Volltextzugriff (PDF)

Lenalidomide (LEN) pharmacokinetics (PKs) in multiple myeloma (MM) patients (pts) with various renal functions

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.8039-8039

2018

Volltextzugriff (PDF)

Low Incidence of Esophageal Toxicity After Lung Stereotactic Body Radiation Therapy: Are Current Esophageal Dose Constraints Too Conservative?

International journal of radiation oncology, biology, physics, 2018-07, Vol.101 (3), p.574-580

2018

Volltextzugriff (PDF)

Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF)

Blood, 2016-12, Vol.128 (22), p.4264-4264

2016

Volltextzugriff (PDF)

Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the Oncomine Comprehensive Assay (OCA) v3: Integrating expanded genomic sequencing into the Canadian publicly funded health care model

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.2620-2620

2019

Volltextzugriff (PDF)

An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines

Leukemia & lymphoma, 2020-07, Vol.61 (8), p.1860-1868

2020

Volltextzugriff (PDF)

A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL)

Leukemia & lymphoma, 2019-03, Vol.60 (4), p.980-989

2019

Volltextzugriff (PDF)

A phase 2 study of ofatumumab (Arzerra®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL)

Leukemia & lymphoma, 2019-01, Vol.60 (1), p.92-100

2019

Volltextzugriff (PDF)

Long‐term follow‐up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia

British journal of haematology, 2014-06, Vol.165 (5), p.731-733

2014

Volltextzugriff (PDF)

Feasibility and acceptability of implementing an electronic patient reported outcome (e-PRO) dysphagia screening tool for routine multidisciplinary care

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.155-155

2017

Volltextzugriff (PDF)

An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)

Blood, 2015-12, Vol.126 (23), p.4163-4163

2015

Volltextzugriff (PDF)

Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients

British journal of cancer, 2016-03, Vol.114 (6), p.616-622

2016

Volltextzugriff (PDF)

Comparison of the Impact of Two Different Definitions of Red-Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF)

Blood, 2014-12, Vol.124 (21), p.3180-3180

2014

Volltextzugriff (PDF)

A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Blood, 2015-12, Vol.126 (23), p.1742-1742

2015

Volltextzugriff (PDF)

Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study

Clinical lymphoma, myeloma and leukemia, 2017-11, Vol.17 (11), p.774-781

2017

Volltextzugriff (PDF)

Metastatic NSCLC: Treatment patterns, outcomes, and costs of newer agents

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.7606-7606

2012

Volltextzugriff (PDF)

An analysis of malignant bowel obstruction (MBO) outcomes in patients with epithelial ovarian carcinoma (EOC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e16586-e16586

2015

Volltextzugriff (PDF)

An Open-Label Phase 2 Study Of Ofatumumab In Combination With a Novel AKT Inhibitor (Afuresertib) In Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)

Blood, 2013-11, Vol.122 (21), p.4175-4175

2013

Volltextzugriff (PDF)

Assessment of single screening questions for dysphagia for routine clinical use in a tertiary care practice

Journal of clinical oncology, 2014-10, Vol.32 (30_suppl), p.102-102

2014

Volltextzugriff (PDF)

Long-Term Follow-up of a Phase 2 Study of Single Agent Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)

Blood, 2012-11, Vol.120 (21), p.718-718

2012

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(38)

Sprache

Englisch
(38)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(19)
Science & Technology
(19)
Humans
(16)
Female
(13)
Oncology
(13)
Middle Aged
(12)
Aged
(11)
Male
(10)
Adult
(9)
Aged, 80 And Over
(7)
Retrospective Studies
(6)
Hematology
(5)
Treatment Outcome
(5)
Biological And Medical Sciences
(4)
Follow-Up Studies
(4)
Medical Sciences
(4)
Toxicity
(4)
Cohort Studies
(3)
Combined Modality Therapy
(3)
Diabetes Mellitus, Type 2 - Complications
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Effect of Red Blood Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm-Associated Myelofibrosis

Real‐world chemotherapy treatment patterns in metastatic non–small cell lung cancer: Are patients undertreated?

A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

Patient-reported acute fatigue in elderly breast cancer patients treated with and without regional nodal radiation

Ultracentral Tumors Treated With Stereotactic Body Radiotherapy: Single-Institution Experience

Lenalidomide (LEN) pharmacokinetics (PKs) in multiple myeloma (MM) patients (pts) with various renal functions

Low Incidence of Esophageal Toxicity After Lung Stereotactic Body Radiation Therapy: Are Current Esophageal Dose Constraints Too Conservative?

Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF)

Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the Oncomine Comprehensive Assay (OCA) v3: Integrating expanded genomic sequencing into the Canadian publicly funded health care model

An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines

A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL)

A phase 2 study of ofatumumab (Arzerra®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL)

Long‐term follow‐up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia

Feasibility and acceptability of implementing an electronic patient reported outcome (e-PRO) dysphagia screening tool for routine multidisciplinary care

An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)

Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients

Comparison of the Impact of Two Different Definitions of Red-Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF)

A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study

Metastatic NSCLC: Treatment patterns, outcomes, and costs of newer agents

An analysis of malignant bowel obstruction (MBO) outcomes in patients with epithelial ovarian carcinoma (EOC)

An Open-Label Phase 2 Study Of Ofatumumab In Combination With a Novel AKT Inhibitor (Afuresertib) In Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)

Assessment of single screening questions for dysphagia for routine clinical use in a tertiary care practice

Long-Term Follow-up of a Phase 2 Study of Single Agent Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)

Suchergebnisse filtern